Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, posted on LinkedIn by Boehringer Ingelheim, adding:
“Three Phase III trials. Three diseases where the standard of care has stood still for long.
Small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (epNEC), resectable HER2 (ERBB2)–mutant non-small cell lung cancer (NSCLC) after surgery. Each one represents a population that has been waiting for something better. Each one is now the focus of a Phase III program at Boehringer Ingelheim.
Both approaches, a DLL3 (delta-like ligand 3)/CD3 T-cell engager and a HER2-targeted therapy, are designed around tumor biology. The questions we keep coming back to: who is most likely to benefit, and how do we get precision medicine to them earlier? Those questions take years to answer, and they reflect the kind of sustained, biology-first thinking that underpins everything we do in oncology.
To the teams, investigators and the people taking part in these studies: your contribution is the foundation of everything we’re building.”
Quoting Boehringer Ingelheim’s post:
“Three Phase III trials now underway in some of the hardest-to-treat cancers.
Two trials advance understanding of an investigational DLL3 (delta-like ligand 3)/CD3 T-cell engager for people facing small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC), where current treatment options remain limited and survival outcomes have not improved in decades.
A third trial moves into earlier-stage HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC), testing a targeted therapy after surgery.
Other articles featuring Lykke Hinsch Gylvin on OncoDaily.